Kura Oncology (KURA) Revenue (2025 - 2026)
Kura Oncology (KURA) posted quarterly Revenue of $18.3 million for Q1 2026, up 29.47% year-over-year from $14.1 million in Q1 2025, and up 5.36% quarter-over-quarter from $17.3 million in Q4 2025.
Kura Oncology (KURA) Revenue (2025 - 2026) Analysis & Trends
Kura Oncology (KURA) has reported Revenue for 2 consecutive years, with $18.3 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Revenue rose 29.47% year-over-year to $18.3 million; the TTM figure through Mar 2026 stood at $71.6 million (changed N/A YoY), while the FY2025 annual figure was $67.5 million, up 25.24% from the prior year.
- Revenue rose to $18.3 million in Q1 2026 per KURA's latest filing, from $17.3 million in the prior quarter.
- Across five years, Revenue topped out at $20.8 million in Q3 2025 and bottomed at $14.1 million in Q1 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Revenue (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 3.33 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 4.29 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 1.56 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 1.71 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 3,001.92 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 674.14 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 1.29 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 425.49 Mn |
| 10 | Kura Oncology | 966.11 Mn | 966.11 Mn | 20.63 Mn | 20.87 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 20.87 Mn |
| Mar 31, 2026 | 18.27 Mn |
| Dec 31, 2025 | 17.34 Mn |
| Sep 30, 2025 | 20.75 Mn |
| Jun 30, 2025 | 15.29 Mn |
| Mar 31, 2025 | 14.11 Mn |